Medicago, Inc. Announces a $3.5 Million Private Placement
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
QUEBEC CITY, April 23, 2013 /CNW Telbec/ - Medicago Inc. ("Medicago" or the "Corporation") (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles ("VLPs"), is pleased to announce that it has entered into an agreement to sell to Le Fonds d'investissement RÉA II Fiera Capital Inc., on a private placement basis, 6,250,000 common shares of the Corporation (the "Common Shares") at a price of $0.56 per share for gross proceeds of $3.5 million (the "Offering").
Help employers find you! Check out all the jobs and post your resume.
QUEBEC CITY, April 23, 2013 /CNW Telbec/ - Medicago Inc. ("Medicago" or the "Corporation") (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles ("VLPs"), is pleased to announce that it has entered into an agreement to sell to Le Fonds d'investissement RÉA II Fiera Capital Inc., on a private placement basis, 6,250,000 common shares of the Corporation (the "Common Shares") at a price of $0.56 per share for gross proceeds of $3.5 million (the "Offering").
Help employers find you! Check out all the jobs and post your resume.